Clinical Trial

Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study. Based on the previous basic research, our company has developed CAR-NK cell injection, hoping to further evaluate its safety, tolerability and preliminary efficacy in the treatment of mCRPC patients in clinical studies, and provide new possibilities for the selection of clinical treatment strategies
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2026-01-21
Trial Details
NCT Number NCT07156045
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Prostate Cancer Castration-resistant Prostate Cancer
Enrollment 10 participants
Start Date 2025-09-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-23